TSH receptor specific monoclonal autoantibody K1‐70 <sup>TM</sup> targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial-Reference-Cited by-同舟云学术

TSH receptor specific monoclonal autoantibody K1‐70 ^TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial

Published:2022-02-06 Issue:6 Volume:96 Page:878-887
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clinical Endocrinology

Author:

Furmaniak Jadwiga¹²^ORCID,Sanders Jane¹²,Sanders Paul²,Li Yang²,Rees Smith Bernard¹²

Affiliation:

1. AV7 Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK

2. RSR Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen.14681

Reference32 articles.

1. Autoantibodies to the Thyrotropin Receptor

2. Mechanisms of Action of TSHR Autoantibodies

3. New Therapeutic Horizons for Graves’ Hyperthyroidism

4. Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves’ disease

5. The long-term follow-up of patients with thionamide-treated Graves’ hyperthyroidism

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Thyroid-Stimulating Hormone Receptor: A Perspective on Small-Molecule Modulators and Their Therapeutic Potential;Journal of Medicinal Chemistry;2024-09-13

2. Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer;Molecular Imaging and Biology;2024-08-22

3. Graves disease: latest understanding of pathogenesis and treatment options;Nature Reviews Endocrinology;2024-07-22

4. Effects of Low-dose Methotrexate With Methimazole in Patients With Graves’ Disease: Results of a Randomized Clinical Trial;The Journal of Clinical Endocrinology & Metabolism;2024-07-12

5. Recent Advances of Second‐Line Targeted Biopharmaceutical Therapies in Thyroid Associated Ophthalmopathy;Advanced Therapeutics;2024-07-05